Description
A previously healthy 3-month-old former 30-week premature girl presented with sudden onset altered mental status and cardiopulmonary arrest.1 CT scan showed a 10.2 cm hyperdense lesion in the right hemisphere with areas of acute haemorrhage causing subfalcine, uncal and inferior cerebellar herniation with obstructive hydrocephalus and diffuse cerebral oedema (figure 1A). She underwent craniotomy with gross total resection noted on postoperative MRI (figure 1B). Neuropathology showed densely cellular, pleomorphic astrocytes with high mitotic rate and glial fibrillary acidic protein (GFAP) positive staining consistent with high-grade glioma (figure 2A). A next-generation cancer gene sequencing panel revealed a novel PPP1CB-anaplastic lymphoma kinase (ALK) gene fusion from PPP1CB intron 5 and ALK intron 19. Variants of unknown significance were also noted on ECT2L, IRS2, KDM6A, NTRK1, TNFRSF17 and XBP1. Based on her young age and extensive surgical resection the decision was made not to undergo radiation or chemotherapy.
The patient had subsequent left hemiparesis, hypotonia, dysphagia and global developmental delay. Surveillance MRI brain at 7 months old showed an asymptomatic trapped right ventricle causing leftward midline shift. She underwent endoscopic cyst fenestration and a second resection at 9 months old with biopsy showing gliosis. The 1-month postoperative MRI brain following the second resection showed a 1.5 cm rim-enhancing nodule in right parietal region second resection site (figure 1C).
Following her second resection, she remained disease free; however, subsequent surveillance MRI brain at 2 years old (figure 1D) and 4 years old (figure 1E) revealed that the residual nodule grew slowly to 1.7 cm (figure 1E). Given concern about residual disease, decision was made to undergo a third gross total resection at 4 years old (figure 1F) that demonstrated a markedly different histopathology from the original high-grade glioma at diagnosis. The tumour was of low cellularity with mature ganglionic cells consistent with a diagnosis of ganglioglioma (figure 2B). Next generation cancer gene sequencing panel revealed the identical PPP1CB-ALK gene fusion along with variants of unknown significance of CASP8 and KDM6A.
ALK is a cell surface receptor tyrosine kinase that promotes downstream PI3K, JAK-STAT and MAPK pathways and has been associated with other various tumours including lymphoma, neuroblastoma and non-small-cell lung cancer.2 ALK gene fusions such as NPM-ALK and EML4-ALK have been reported to function as oncogenes in a variety of cancers.2
We previously reported on PPP1CB-ALK gene fusion as a novel mutation for primary high-grade glioma.1 Low-grade glioma recurrence following gross subtotal resection of a high-grade glioma has been reported.3 Our case highlights that there may be two unique histopathological tumours in the same patient with similar genetic changes. However, without additional functional studies, we cannot be sure if the PPP1CB-ALK fusion is a genetic driver in this disease. Furthermore, we do not know what role, if any, the variants of unknown significance may play. Our case adds to the literature regarding the complexity of infantile brain tumours.
Learning points.
High-grade glioma of infancy may contain both high-grade and low-grade elements with similar tumour genetics.
PPP1CB-anaplastic lymphoma kinase (ALK) gene fusion has been reported in a primary high-grade and low-grade glioma in the same patient.
Further studies are needed to determine if PPP1CB-ALK gene fusion results in a functional fusion protein that may play a role in tumour growth and differentiation.
Footnotes
Patient consent for publication: Obtained.
Contributors: AN was responsible for the design and writing of the manuscript. MLL was responsible for the design and writing of the manuscript. DMM was responsible for the design and writing of the manuscript. JRC was responsible for the design and writing of the manuscript. All authors approve the contents of the manuscript.
Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests: None declared.
Provenance and peer review: Not commissioned; externally peer reviewed.
References
- 1. Aghajan Y, Levy ML, Malicki DM, et al. . Novel PPP1C B-ALK fusion protein in a high-grade glioma of infancy. BMJ Case Rep 2016;10:1136. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013;13:685–700. 10.1038/nrc3580 [DOI] [PubMed] [Google Scholar]
- 3. Horbinski C, Dillon D, Pittman T. Low-grade recurrence of a congenital high-grade supratentorial tumor with astrocytic features in the absence of adjuvant therapy. Neuropathology 2011;31:286–91. 10.1111/j.1440-1789.2010.01156.x [DOI] [PubMed] [Google Scholar]